• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Ponsegromab for the Treatment of Cancer Cachexia

byDaniel GoldshteinandSze Wah Samuel Chan
September 23, 2024
in Chronic Disease, Oncology
Reading Time: 3 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. Ponsegromab at increasing doses resulted in a mean increase in body weight compared to placebo; 1.22 kg (2.21%) in the 100-mg group, 1.92 kg (2.99%) in the 200-mg group, and 2.81 kg (5.46) in the 400-mg group.

2. Adverse events of any cause were reported in 67%-74% in the ponsegromab group vs 80% in the placebo group, with most (88%) being mild to moderate.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Cachexia is a multifactorial syndrome seen in cancer patients with limited pharmacologic treatment options available. It was found that the GDF-15 pathway is a key modulator of anorexia and body-weight regulation, and elevated GDF-15 levels are linked to weight loss, muscle wasting, and reduced survival in cancer patients. A promising treatment, ponsegromab, targets the GDF-15 pathway and has shown improvements in weight, appetite, and physical activity in early trials. This is a phase 2 trial that assessed the safety and efficacy of ponsegromab, as compared with placebo in patients with cancer cachexia who had elevated circulating GDF-15 levels. The primary endpoint was the change in body weight and secondary endpoints included patient-reported outcomes such as change in cachexia scales, physical activity and gait. At 12 weeks, the increase in weight compared to placebo was higher in the experimental arm with greater increases with the higher dosage. Weight changes were consistent with GDF-15 suppression at 12 weeks. Patient-reported outcomes on cachexia scales showed improvements in the 100-mg and 400-mg ponsegromab groups vs the placebo group at 12 weeks however no differences in the score were seen in the 200-mg ponsegromab group relative to the placebo group. Regarding physical activity, it was found that patients in the 400-mg ponsegromab group had increased overall activity compared with the placebo group. The most common adverse events are diarrhea, cancer progression, anemia, hypokalemia, nausea, vomiting, and pyrexia. Most of the adverse events (88%) were mild to moderate. The strengths of this study included its methodology and the limitations included the small sample size, the follow-up period, and only including patients with elevated CDF-15 levels. Overall, this study found that ponsegromab at increasing doses resulted in a reduction in cachexia symptoms and increases in body weight as compared with placebo in patients with cancer cachexia and an elevated circulating GDF-15 level.

Click to read the study in the NEJM (New England Journal of Medicine)

Click to read an accompanying editorial in NEJM

RELATED REPORTS

Ponsegromab improves boy weight in cancer-related cachexia

Relevant Reading: The GDF15-GFRAL Pathway in Health and Metabolic Disease: Friend or Foe?

In-Depth [randomized controlled trial]: This international, double-blind study enrolled patients with NSCLC, pancreatic cancer, or colorectal cancer with defined cachexia and an elevated serum GDF-15 level, and randomized them (1:1:1:1) to ponsegromab at a dose of 100 mg (n=46), 200 mg (n=46), or 400 mg (n=50) or to receive placebo (n=45), respectively. The median interval from cancer diagnosis to randomization was 11.7 months (4.0-26.4). The ponsegromab 400-mg group had the highest proportion of patients with stage IV disease (86% vs 65-74% in the other three groups). At 12 weeks, the increase in weight compared to placebo was 1.22 kg (95%CI, 0.37-2.25, p<0.05) in the 100-mg group, 1.92 kg (95%CI, 0.92-2.97, p<0.05) in the 200-mg group, and 2.81 kg (95%CI, 1.55-4.08, p<0.05) in the 400-mg group. This correlated to a mean percent change from baseline in body weight of 2.21% (95%CI, –0.20-4.46) in the 100-mg group, 2.99% (95%CI, 0.64-5.35) in the 200-mg group, and 5.46% (95%CI, 3.05-7.87) in the 400-mg group. Changes in weight were consistent with GDF-15 suppression at 12 weeks, with a median factor change from baseline in the unbound GDF-15 level of 0.15 (interquartile range, 0.03-1.02) in the 100-mg group, 0.07 (0.02-0.75) in the 200-mg group, and 0.02 (0.02-0.04) in the 400-mg group, as compared with 1.02 (0.74 to 1.40) in the placebo group. Patient-reported outcomes on cachexia scales showed improvements in the 100-mg and 400-mg ponsegromab groups vs the placebo group at 12 weeks however no differences in the score were seen in the 200-mg ponsegromab group relative to the placebo group. Regarding physical activity, it was found that patients in the 400-mg ponsegromab group had increased overall activity compared with the placebo group, with a difference of 72 minutes (95%CI, 37-107) per day. An exploratory endpoint that was investigated was a change in lumbar skeletal muscle index which found a difference of 2.04 cm2 per square meter (95%CI, 0.27-3.83) in the 400-mg ponsegromab group compared to the placebo group. With regards to safety, adverse events of any cause were reported in 67%-74% of the ponsegromab group compared to 80% in the placebo group, with the most common adverse events being diarrhea, cancer progression, anemia, hypokalemia, nausea, vomiting, and pyrexia. Most of the adverse events (88%) were mild to moderate. Overall, this study found that ponsegromab at increasing doses resulted in a reduction in cachexia symptoms and increases in body weight as compared with placebo in patients with cancer cachexia and an elevated circulating GDF-15 level.

Image: PD

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cancer cachexiaGDF-15ponsegromab
Previous Post

Datopotamab deruxtecan may be a novel improvement for inoperable breast cancer

Next Post

Semaglutide reduces heart failure events in patients with preserved ejection fraction

RelatedReports

Cancer weight and muscle loss collage: a smiling white-haired woman in a sweater, a steaming bowl of soup, a spoon and bread
Oncology

Ponsegromab improves boy weight in cancer-related cachexia

March 4, 2025
Next Post
Parental conceptions of weight are becoming increasingly inaccurate

Semaglutide reduces heart failure events in patients with preserved ejection fraction

Adaptimmune’s Afami-cel is the first FDA-approved T-cell receptor therapy for synovial sarcoma

#VisualAbstract: Insulin Efsitora is Noninferior to Degludec in Type 2 Diabetes without Previous Insulin Treatment

#VisualAbstract: Insulin Efsitora is Noninferior to Degludec in Type 2 Diabetes without Previous Insulin Treatment

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Ibuprofen is associated with acute kidney injury in high-risk inpatients but not low-risk.
  • Thoracic epidural and paravertebral blockade have similar efficacy for reduction of chronic post-thoracotomy pain
  • Brepocitinib improved cutaneous sarcoidosis activity compared to placebo in phase II of BEACON trial.
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.